Can-Fite BioPharma Ltd. (TLV:CANF)
1.500
0.00 (0.00%)
Apr 24, 2025, 5:24 PM IDT
Can-Fite BioPharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 4.83 | 4.28 | 2.98 | 4.39 | 8.27 | Upgrade
|
Short-Term Investments | 3.06 | 4.64 | 5 | 14.51 | - | Upgrade
|
Trading Asset Securities | - | - | 0.01 | 0.24 | 0.08 | Upgrade
|
Cash & Short-Term Investments | 7.89 | 8.92 | 7.99 | 19.14 | 8.34 | Upgrade
|
Cash Growth | -11.60% | 11.71% | -58.27% | 129.40% | 202.17% | Upgrade
|
Prepaid Expenses | 1.02 | 0.91 | 1.12 | 0.88 | 1.04 | Upgrade
|
Other Current Assets | 0.08 | 0.08 | 0.05 | 0.05 | 0.02 | Upgrade
|
Total Current Assets | 8.98 | 9.91 | 9.16 | 20.07 | 9.4 | Upgrade
|
Property, Plant & Equipment | 0.14 | 0.08 | 0.13 | 0.19 | 0.12 | Upgrade
|
Total Assets | 9.12 | 9.99 | 9.28 | 20.25 | 9.52 | Upgrade
|
Accounts Payable | 0.62 | 0.43 | 0.9 | 0.95 | 0.56 | Upgrade
|
Accrued Expenses | 0.98 | 0.94 | 0.78 | 0.91 | 0.33 | Upgrade
|
Current Portion of Leases | 0.05 | 0.03 | 0.05 | 0.05 | 0.04 | Upgrade
|
Current Unearned Revenue | 0.41 | 0.62 | 0.78 | 0.82 | 0.33 | Upgrade
|
Total Current Liabilities | 2.05 | 2.02 | 2.5 | 2.73 | 1.27 | Upgrade
|
Long-Term Leases | 0.05 | 0.01 | 0.01 | 0.07 | 0.02 | Upgrade
|
Long-Term Unearned Revenue | 1.58 | 1.71 | 2.3 | 3.07 | 2.16 | Upgrade
|
Total Liabilities | 3.68 | 3.75 | 4.81 | 5.87 | 3.45 | Upgrade
|
Common Stock | - | - | - | - | 33.04 | Upgrade
|
Additional Paid-In Capital | 170.67 | 163.6 | 154.19 | 153.93 | 97.38 | Upgrade
|
Retained Earnings | -166.36 | -158.48 | -150.85 | -140.67 | -125.47 | Upgrade
|
Comprehensive Income & Other | 1.13 | 1.13 | 1.13 | 1.13 | 1.13 | Upgrade
|
Total Common Equity | 5.44 | 6.24 | 4.47 | 14.38 | 6.07 | Upgrade
|
Shareholders' Equity | 5.44 | 6.24 | 4.47 | 14.38 | 6.07 | Upgrade
|
Total Liabilities & Equity | 9.12 | 9.99 | 9.28 | 20.25 | 9.52 | Upgrade
|
Total Debt | 0.1 | 0.04 | 0.06 | 0.12 | 0.07 | Upgrade
|
Net Cash (Debt) | 7.78 | 8.88 | 7.93 | 19.02 | 8.28 | Upgrade
|
Net Cash Growth | -12.37% | 12.08% | -58.32% | 129.76% | 208.12% | Upgrade
|
Net Cash Per Share | 0.00 | 0.01 | 0.01 | 0.03 | 0.02 | Upgrade
|
Filing Date Shares Outstanding | 3,106 | 1,497 | 1,225 | 815.75 | 515.75 | Upgrade
|
Total Common Shares Outstanding | 2,983 | 1,360 | 815.75 | 815.75 | 463.77 | Upgrade
|
Working Capital | 6.93 | 7.89 | 6.66 | 17.34 | 8.13 | Upgrade
|
Book Value Per Share | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | Upgrade
|
Tangible Book Value | 5.44 | 6.24 | 4.47 | 14.38 | 6.07 | Upgrade
|
Tangible Book Value Per Share | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | Upgrade
|
Machinery | 0.08 | 0.28 | 0.28 | 0.27 | 0.26 | Upgrade
|
Leasehold Improvements | - | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
Updated Aug 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.